Aavogen Inc.
Rockville, MD
- UEI
- D7WBG8G7AWE4
- CAGE
- 7R8K5
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 13420 Glen Lea Way, Rockville, MD 20850, USA
- Website
- aavogen.com
- Founded
- 2015
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- Health & Wellness
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Preclinical validation of AVGN7 for treating obesity and type 2 diabetes mellitus. - project summary. Obesity is the… | National Institute of Diabetes and Digestive and Kidney Diseases | $350,000 | |
| Development of optimized adeno-associated viral capsids for muscle gene therapy - project summary. Gene therapeutics… | National Insititue of Arthritis and Musculoskeletal and Skin Diseases | $554,456 | |
| Preclinical development of a novel gene therapeutic for inclusion body myositis - project summary. Gene therapy offers… | National Institute on Aging | $2,781,674 | |
| Preclinical validation of AVGN7 for treating duchenne muscular dystrophy | National Insititue of Arthritis and Musculoskeletal and Skin Diseases | $224,999 | |
| AVGN7, a novel gene therapeutic for treating cancer cachexia | National Cancer Institute | $2,271,618 |
About Aavogen Inc.
Aavogen Inc. is a biotechnology company located in Rockville, Maryland, focused on developing advanced gene therapeutic technologies targeting muscle-related diseases and metabolic conditions. Registered in SAM.gov since November 2016, the company specializes in developing gene therapeutics that enhance skeletal muscle mass and function, with a particular emphasis on addressing complex medical challenges such as obesity, type 2 diabetes, and rare muscle disorders. The organization is structured as a for-profit corporate entity and has demonstrated significant research capabilities in developing innovative genetic interventions.
Aavogen Inc. has secured multiple federal grant awards from prominent research agencies, including the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Institute of Arthritis and Musculoskeletal and Skin Diseases, and the National Institute on Aging. These grants, totaling substantial research funding, support critical preclinical developments in gene therapy technologies. The company's primary research focus involves developing AVGN7, a gene therapeutic designed to enhance skeletal muscle mass and function by targeting the myostatin/activin receptor signaling pathway. Specific research projects include preclinical validation of AVGN7 for treating obesity and type 2 diabetes, developing optimized adeno-associated viral capsids for muscle gene therapy, and advancing a novel gene therapeutic approach for inclusion body myositis. Each project demonstrates the company's commitment to addressing complex medical challenges through sophisticated genetic engineering and therapeutic interventions.
Quick answers
What is Aavogen Inc.'s UEI?
Aavogen Inc.'s Unique Entity ID (UEI) in SAM.gov is D7WBG8G7AWE4.
What is Aavogen Inc.'s CAGE code?
Aavogen Inc.'s CAGE code is 7R8K5.
What is Aavogen Inc.'s primary NAICS code?
Aavogen Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Aavogen Inc. located?
Aavogen Inc.'s physical address in SAM.gov is 13420 Glen Lea Way, Rockville, MD 20850, USA.
Is Aavogen Inc. registered in SAM.gov?
Yes. Aavogen Inc.'s SAM.gov registration is active through July 27, 2027.
What is Aavogen Inc.'s most recent federal award?
Aavogen Inc.'s most recent federal grant award is Preclinical validation of AVGN7 for treating obesity and type 2 diabetes mellitus. - project summary. Obesity is the… (R43DK145239), from National Institute of Diabetes and Digestive and Kidney Diseases, on September 5, 2025.
On GovTribe
See Aavogen Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors